Trastuzumab Deruxtecan

Introduction

Trastuzumab Deruxtecan is an advanced anticancer medication used primarily for the treatment of HER2-positive cancers, including breast and gastric cancers. It is an antibody-drug conjugate (ADC), combining trastuzumab (a monoclonal antibody) with deruxtecan (a chemotherapy agent). This unique formulation allows targeted delivery of chemotherapy directly to cancer cells while minimizing damage to healthy cells. Trastuzumab Deruxtecan is typically prescribed when other HER2-targeted therapies are ineffective, providing hope for patients with advanced or metastatic cancer. It is administered under strict medical supervision in a hospital or clinical setting.

Uses of Trastuzumab Deruxtecan

• Treatment of HER2-positive metastatic breast cancer
• Management of HER2-positive gastric or gastroesophageal junction cancer
• HER2-low breast cancer (in specific indications)
• Used when prior HER2-targeted therapies have failed

How Trastuzumab Deruxtecan Works

Trastuzumab Deruxtecan targets HER2 receptors on cancer cells using the trastuzumab antibody. Once bound, the deruxtecan payload is released directly into the cancer cells, destroying them from within. This targeted approach minimizes damage to healthy cells and improves treatment effectiveness.

Benefits of Trastuzumab Deruxtecan

• Highly targeted therapy for HER2-positive and HER2-low cancers
• Effective when other HER2 therapies fail
• Improved progression-free survival rates in clinical studies
• Delivers chemotherapy directly to cancer cells
• Reduces systemic toxicity compared to traditional chemotherapy

How to Take Trastuzumab Deruxtecan

Trastuzumab Deruxtecan is administered as an intravenous (IV) infusion by a healthcare professional, typically every three weeks. The dose is calculated based on body weight and clinical condition. Patients are monitored closely during and after infusion for any adverse reactions. Always follow your oncologist’s dosage instructions precisely.

Type of Dosage Available

• Intravenous injection (IV infusion)
• Available in single-use vial formulation

Side Effects of Trastuzumab Deruxtecan

• Nausea and vomiting
• Fatigue
• Hair loss (alopecia)
• Low white blood cell count (neutropenia)
• Lung toxicity or interstitial lung disease (rare but serious)
• Infusion-related reactions

Safety Advice

• Not recommended during pregnancy or breastfeeding
• Regular blood tests and lung monitoring are essential
• Inform your doctor of any breathing issues or persistent cough
• Use effective contraception during treatment and for 7 months after
• Avoid live vaccines during treatment

Frequently Asked Questions (FAQs)

Q: What is Trastuzumab Deruxtecan used for?

A: It is used to treat HER2-positive and HER2-low breast and gastric cancers that have not responded to other treatments.

Q: How is Trastuzumab Deruxtecan given?

A: It is administered as an intravenous infusion in a hospital or clinic every three weeks.

Q: What are the serious side effects of this medicine?

A: Lung toxicity (interstitial lung disease), low blood counts, and infusion reactions are among the serious but rare side effects.

Q: Can pregnant women take Trastuzumab Deruxtecan?

A: No, it is not recommended during pregnancy due to potential harm to the fetus.

Q: Do I need special monitoring during treatment?

A: Yes, your doctor will monitor your blood counts, lung function, and overall health regularly during treatment.